汇丰环球研究发表报告表示,将石药集团(01093.HK) 评级从“持有”上调至“买入”,目标价从4.7元上调至9.5元,对其估值由综合估值方式改为按现金流折现率估算,潜在升幅21%。该行指石药今年首季度收入和净利润分别按年下降22%和8%,但产品销售和利润按季增长12%和60%,显示出从集中采购(VBP)压力下的逐步复苏。同时,该行对石药集团的创新药物更加乐观,原因如下:1)石药集团今年5月30日...
Source Link汇丰环球研究发表报告表示,将石药集团(01093.HK) 评级从“持有”上调至“买入”,目标价从4.7元上调至9.5元,对其估值由综合估值方式改为按现金流折现率估算,潜在升幅21%。该行指石药今年首季度收入和净利润分别按年下降22%和8%,但产品销售和利润按季增长12%和60%,显示出从集中采购(VBP)压力下的逐步复苏。同时,该行对石药集团的创新药物更加乐观,原因如下:1)石药集团今年5月30日...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.